News &amp; Updates

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Antioxidant supplementation in men seeking fertility care does not improve pregnancy rates

The use of antioxidant supplements in men seeking fertility care does not appear to increase the chances of conceiving for their female partners, as shown in the multicentre SUMMER trial.

Antioxidant supplementation in men seeking fertility care does not improve pregnancy rates

Infliximab superior to adalimumab in bio-naïve patients with FCD

A recent study has shown infliximab’s superiority over adalimumab in the treatment of bio-naïve patients with fistulizing Crohn’s disease (FCD). However, there is no therapeutic difference seen in bio-exposed FCD.

Infliximab superior to adalimumab in bio-naïve patients with FCD

Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials

07 Oct 2025 by

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.

Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials

07 Oct 2025

Novel cannabinoid receptor 1 inverse agonist a promising medication for obesity

Treatment with the novel cannabinoid receptor 1 (CB1R) inverse agonist monlunabant appears to yield significant and clinically meaningful weight loss in adults with obesity and metabolic syndrome, according to a phase IIa trial.

Novel cannabinoid receptor 1 inverse agonist a promising medication for obesity

Boosting potassium wards off ventricular arrhythmias in patients with ICD

07 Oct 2025 by

Increasing low potassium levels improves clinical outcomes in patients with cardiovascular disease (CVD) and a high risk for ventricular arrhythmias, as shown in the POTCAST trial presented at ESC 2025.

Boosting potassium wards off ventricular arrhythmias in patients with ICD

07 Oct 2025

Teprotumumab outclasses glucocorticoids in thyroid eye disease

Compared with intravenous (IV) or oral glucocorticoids (GCs), the use of teprotumumab results in lower risks of mortality and cardiovascular, renal, and infectious outcomes in patients with thyroid eye disease (TED), suggests a study.

Teprotumumab outclasses glucocorticoids in thyroid eye disease

Enoxaparin, nadroparin help accelerate wound healing

Treatment with enoxaparin and nadroparin may speed up wound healing after an operation, reports a study. On the other hand, phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) may delay recuperation.

Enoxaparin, nadroparin help accelerate wound healing

Prenatal antidepressant exposure may elevate risk of postpartum haemorrhage

Women with prenatal exposure to selective serotonin and serotonin-norepinephrine reuptake inhibitors appear to be at increased risk of postpartum haemorrhage, according to a study.

Prenatal antidepressant exposure may elevate risk of postpartum haemorrhage